Patents Examined by Lakshmi Channavajjala
  • Patent number: 9993439
    Abstract: The present disclosure relates generally to a mucoadhesive nanoparticle delivery system. The nanoparticles are formed from amphiphilic macromolecules conjugated to a mucosal targeting moiety in such a manner that the surface of the nanoparticle is coated with the targeting moiety. The surface density of the targeting moiety can be tuned for adjustable targeting of the nanoparticles to a mucosal site without substantially compromising the stability of the particles. The particles were found to have high loading efficiency and sustained release properties at the mucosal site. The present disclosure also relates to polymers and macromolecules useful in the preparation of the mucoadhesive nanoparticles, as well as compositions, methods, commercial packages, kits and uses related thereto.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: June 12, 2018
    Assignee: UNIVERSITY OF WATERLOO
    Inventors: Frank X. Gu, Lyndon William James Jones, Shengyan (Sandy) Liu
  • Patent number: 9968556
    Abstract: Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: May 15, 2018
    Assignee: TheraVida, Inc.
    Inventors: Mehdi Paborji, Robert V. Tuohy, III, Peter R. P. Freed, Roger S. Flugel
  • Patent number: 9962446
    Abstract: A solid dispersion comprising at least one active ingredient in at least one hydroxyalkyl methylcellulose having a DS of from 1.0 to 2.7 and an MS of from 0.40 to 1.30, wherein DS is the degree of substitution of methoxyl groups and MS is the molar substitution of hydroxyalkoxyl groups, can be produced by extrusion or spray-drying.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: May 8, 2018
    Assignee: Dow Global Technologies LLC
    Inventors: Nicholas S. Grasman, Steven J. Guillaudeu, Mark J. Hall, Uma Shrestha, Maureen L. Rose, William W. Porter, III, Wesley J. Spaulding, Kevin P. O'donnell, True L. Rogers
  • Patent number: 9926409
    Abstract: The present invention relates to a organopolysiloxane graft polymer including an organopolysiloxane segment as a main chain thereof and an unsaturated monomer-derived polymer segment as a side chain thereof, in which the unsaturated monomer-derived polymer segment contains a repeating unit derived from N,N-dimethyl acrylamide in an amount of not less than 50% by mass and not more than 100% by mass, and a content of the organopolysiloxane segment in the organopolysiloxane graft polymer is not less than 10% by mass and not more than 70% by mass.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: March 27, 2018
    Assignee: KAO CORPORATION
    Inventors: Tomoka Maekawa, Shuichiro Kobaru, Chihiro Miyazaki
  • Patent number: 9925091
    Abstract: A wound care bandage for treating a wound is provided. The bandage includes an SIS layer to be placed on the wound surface and a cover to be placed over the wound. The bandage further includes a structure to provide a vacuum space. A method for promoting wound healing is further provided. The method includes applying the above-mentioned wound care bandage to the wound and creating a vacuum in the vacuum space to draw blood controllably from the wound into the SIS layer.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: March 27, 2018
    Assignee: KCI Medical Resources Unlimited Company
    Inventor: Arthur C. Coffey
  • Patent number: 9884016
    Abstract: The present disclosure provides ready-to-use, oil/water emulsion compositions with mean droplet size (intensity-average, nm) of 100-500 nm, where the oil phase comprises clopidogrel free base dispersed in pharmaceutical acceptable oil(s). The emulsion uses clopidogrel free base or premix of clopidogrel free base in oil(s) as the starting materials and may also contain one or more excipients such as surfactant and or co-surfactant, osmotic agent, pH adjustment agent, antioxidant, preservative, sweetener, and/or suspending agent, etc.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: February 6, 2018
    Inventor: Jingjun Huang
  • Patent number: 9867763
    Abstract: A micro-scale heterogeneous emulsion is provided. In some examples, the micro-scale heterogeneous emulsion can include at least two internal phases and an external phase. A method of producing a micro-scale heterogeneous emulsion is also disclosed herein. A method of providing a stable, custom cosmetic composition is also disclosed herein.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: January 16, 2018
    Assignee: Noxell Corporation
    Inventor: Matthew Clair Ehrman
  • Patent number: 9820982
    Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphine which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: November 21, 2017
    Assignee: ENDO PHARMACEUTICALS INC.
    Inventors: Huai-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
  • Patent number: 9814690
    Abstract: Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, selected from the group consisting of (a) polyacrylamide gelling agents, (b) gelling agents which are acrylic polymers coupled to hydrophobic chains, (c) modified starch gelling agents, and mixture thereof, said composition maintaining good chemical stability of (i) and (ii) without their degradation over time at a temperature of between 4° C. and 40° C.
    Type: Grant
    Filed: March 24, 2008
    Date of Patent: November 14, 2017
    Assignee: Galderma Research & Development
    Inventors: Sandrine Orsoni, Nathalie Willcox
  • Patent number: 9814667
    Abstract: A method for producing aqueous silicone emulsions containing highly viscous polyorganosiloxanes having a low content of cyclic siloxanes in several steps; the addition of acidic compounds intended to catalyze polycondensation of the polyorganosiloxanes being carried out only after an emulsion is produced in the first step exclusively with nonionogenic emulsifiers, without impairing the rate of the polycondensation reaction.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: November 14, 2017
    Assignee: WACKER CHEMIE AG
    Inventors: Holger Rautschek, Marco Kauschke
  • Patent number: 9801935
    Abstract: Influenza vaccines are administered using solid biodegradable microneedles. The microneedles are fabricated from the influenza vaccine in combination with solid excipient(s) and, after penetrating the skin, they dissolve in situ and release the vaccine to the immune system. The influenza vaccine is (i) a purified influenza virus surface antigen vaccine, rather than a live vaccine or a whole-virus or split inactivated vaccine (ii) an influenza vaccine prepared from viruses grown in cell culture, not eggs, (iii) a monovalent influenza vaccine e.g. for immunizing against a pandemic strain, (iv) a bivalent vaccine, (v) a tetravalent or >4-valent vaccine, (vi) a mercury-free vaccine, or (vii) a gelatin-free vaccine.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: October 31, 2017
    Assignee: SEQIRUS UK LIMITED
    Inventors: Derek O'Hagan, Manmohan Singh, Sung-Yun Kwon
  • Patent number: 9782514
    Abstract: The present application relates to a film forming composition for application to mammalian skin, which composition comprises at least one polyurethane based polymer together with at least one acrylate based polymer. The film forming composition provides effective skin coating with good adhesion to the skin, and may be used as a skin protector or a wound dressing.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: October 10, 2017
    Assignee: MED-TRADE PRODUCTS LIMITED
    Inventors: Craig Julian Hardy, Andrew Darby
  • Patent number: 9764068
    Abstract: There is described inter alia a device having a surface comprising a layered coating wherein the outer coating layer comprises a plurality of cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1,000 Da (ii) a total molecular weight of 1,500 to 1,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80:1 and (iv) functional end groups, whereby one or more of said functional end groups have an anti-coagulant entity covalently attached thereto.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: September 19, 2017
    Assignee: W.L. Gore and Associates Inc.
    Inventors: Karin Leontein, Per Antoni, Daniel Nyström, Paul Begovac, Krzysztof Pietrzak
  • Patent number: 9724325
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: August 8, 2017
    Assignee: Humanetics Corporation
    Inventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Patent number: 9724397
    Abstract: The present invention relates to a parenteral, sustained and controlled release, semisolid formulation comprising an end-capped oligomer and at least one active substance without any supplementary viscosity reducing agent or excipient.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: August 8, 2017
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Roland Cherif-Cheikh, Anne-Paula De Sousa Delgado, Frédéric Lacombe, Laurence Lachamp, Didier Bourissou
  • Patent number: 9713611
    Abstract: The present invention relates to a composition comprising pharmaceutical active ingredients which are susceptible to, or have potential for, abuse. The invention provides an oral pharmaceutical composition comprising a first population of beads and a second population of beads. The first bead population comprises a pharmaceutically active ingredient susceptible to, or having the potential for, abuse. The second bead population comprises a gelling agent and a coating substantially surrounding the gelling agent, but containing no pharmaceutically active ingredient. The first bead population and the second bead population are physically separable, but visually indistinguishable to the naked eye. Upon ingress of water into the second population of beads, the gelling agent is caused to swell forming a viscous mass inhibiting or preventing the extraction of the active ingredient.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: July 25, 2017
    Assignee: Recro Gainesville, LLC
    Inventors: Gurvinder Singh Rekhi, Richard Sidwell
  • Patent number: 9707312
    Abstract: Kit for producing a bone cement paste, comprising a paste A and a paste B; paste A comprising at least one monomer for radical polymerization, at least one peroxide polymerization initiator and at least one tertiary amine, at least one amidine or a mixture of a tertiary amine and amidine; paste B comprising at least one monomer for radical polymerization, at least one heavy metal compound as polymerization accelerator, and as polymerization co-accelerator at least one sulfimide, at least one dicarboxylic acid imide or a mixture thereof, at least one of the pastes A and B comprising at least one filling agent that is insoluble in the monomer of paste A and/or the monomer of paste B.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: July 18, 2017
    Assignee: HERAEUS MEDICAL GMBH
    Inventor: Sebastian Vogt
  • Patent number: 9693936
    Abstract: The present disclosure is directed to dispersions of a Dead Sea material in oil, the Dead Sea material is present in the dispersions in the form of solid nanoparticles. Further disclosed are formulations comprising the dispersions, method of treating and/or preventing diseases or disorders of the skin comprising topical application of the dispersions or formulations thereof onto a skin of a subject, method of inducing a heat sensation on the skin of a subject by topically applying the dispersions or formulations thereof onto a skin of a subject and methods of preparing the dispersions.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: July 4, 2017
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., AHAVA—DEAD SEA LABORATORIES LTD.
    Inventors: Shlomo Magdassi, Liraz Larush, Chani Mendelson, Miriam Oron, Zeevi Maor, Isabelle Rachel Afriat-Staloff, Marina Privorotski
  • Patent number: 9693962
    Abstract: A dry-coated tablet 1 comprises an inner core 2 which contains an active component and an outer layer 3 which contains powdery solid components and coats the inner core 2. Openings 8c and 9c are formed in circular surfaces 2a and 2b respectively of the inner core 2, wherein each of the openings is larger than the average particle size of a component the average particle size of which is the smallest of the powdery solid components contained in the outer layer 3, and the inner surface 3a of the outer layer 3 penetrates in the openings 8c and 9c.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: July 4, 2017
    Assignee: Takeda Pharmaceutical Limited
    Inventor: Tetsuya Kawano
  • Patent number: 9682075
    Abstract: Tamper-resistance pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: June 20, 2017
    Assignee: COLLEGIUM PHARMACEUTICAL, INC.
    Inventors: Roman Rariy, Alison Fleming, Jane C. Hirsh, Said Saim, Ravi K. Varanasi